List of Excipients in Branded Drug DOJOLVI

« Back to Dashboard

# DOJOLVI Excipient Strategy and Commercial Opportunities in Triheptanoin Formulation

Last updated: August 25, 2026

DOJOLVI is an oral liquid composed of triheptanoin, a synthetic seven-carbon triglyceride, without a conventional pharmacologically inactive excipient system identified in the U.S. prescribing information. Its commercial protection is therefore concentrated in the active ingredient, manufacturing controls, dosing system, regulatory exclusivity, clinical evidence, and disease-specific distribution rather than in a complex formulation platform. The strongest excipient opportunities are adjacent products that improve administration, stability, dose measurement, taste, packaging, and compatibility with enteral feeding.

What is DOJOLVI and what role do excipients play?

DOJOLVI is a prescription oral liquid containing triheptanoin. The FDA approved it in June 2020 for the treatment of adults and children with long-chain fatty acid oxidation disorders, including defects involving the carnitine-acylcarnitine translocase, carnitine palmitoyltransferase II, very-long-chain acyl-CoA dehydrogenase, long-chain 3-hydroxyacyl-CoA dehydrogenase, trifunctional protein, and carnitine palmitoyltransferase I pathways [1].

Triheptanoin is both the active pharmaceutical ingredient and the principal oil phase. The product is administered orally or through an enteral feeding tube and is dosed according to body weight and caloric requirements. The approved product is supplied as a liquid in a 500 mL bottle [1].

The formulation has several strategic consequences:

Formulation characteristic	Commercial consequence
Triheptanoin is the dominant product component	Limited room for conventional filler, binder, disintegrant, or coating innovation
Oral liquid dosage form	Opportunities in metering, bottle design, adapters, and dose delivery
High caloric contribution	Excipients can affect dietary calculations and disease management
Rare metabolic disease indication	Small patient population but high treatment value and specialized distribution
Use in children and feeding-tube patients	Palatability, viscosity, compatibility, and administration burden are commercially important
Lipid-based formulation	Oxidative stability, container closure, and material compatibility require control

The FDA label directs administration with food and establishes dose escalation and dietary management requirements. This makes product usability more important than in many conventional oral liquids because the product is part of a broader metabolic nutrition regimen [1].

What excipients are used in DOJOLVI?

The U.S. label identifies DOJOLVI as triheptanoin oral liquid and does not describe a conventional excipient blend comparable to those used in tablets, aqueous solutions, or suspensions. The approved formulation is not positioned as a flavor-masked, buffered, emulsified, or preserved oral liquid.

The practical formulation strategy is therefore one of excipient avoidance. Removing conventional excipients can reduce risks associated with:

• Long-chain fatty acid exposure
• Carbohydrate loading
• Osmolality changes
• Allergens
• Preservative intolerance
• Drug-excipient degradation
• Enteral tube incompatibility
• Additional caloric contributions

For a metabolic disorder product, excipient selection is not neutral. A lipid, carbohydrate, surfactant, or flavor system can alter the patient’s prescribed diet or create an unrecognized source of metabolic substrate. Any reformulation would require assessment of caloric value, fatty acid composition, tolerability, and effects on disease-specific biochemical monitoring.

What excipient strategies could improve DOJOLVI administration?

The highest-value opportunities are delivery-system strategies rather than replacement excipients inside the liquid.

Taste and mouthfeel improvement

Triheptanoin has an oily texture and can create a substantial administration burden, particularly in children. A taste-management strategy could use:

• Compatible flavor systems
• Food-compatible masking agents
• Microencapsulated flavor components
• Low-calorie or noncaloric sweetening systems
• Premeasured flavored dosing cups or sachets
• Co-administered food matrices

The central constraint is that any flavor or masking system must not introduce clinically meaningful long-chain fats, excess carbohydrates, or metabolic substrates. A flavor system that is acceptable for a standard oral medicine may be unsuitable for patients following tightly controlled fat and carbohydrate regimens.

A commercially attractive approach would be a co-packaged, ready-to-use administration aid rather than a changed drug formulation. That strategy could improve adherence while reducing the regulatory risk of changing the approved drug product.

Dose measurement and pediatric usability

DOJOLVI dosing is weight-based and may involve repeated administration. A specialized delivery kit could include:

• Graduated oral syringes designed for viscous oils
• Low-residual-volume syringes
• Bottle adapters that reduce spills
• Color-coded syringe sizes for pediatric doses
• Tamper-evident closures
• Dose-tracking labels
• Enteral feeding-tube connectors

These components may support standalone device patents, design protection, or combination-product claims. Their commercial value is strongest if they reduce dose loss, simplify caregiver training, and improve administration through feeding tubes.

Enteral feeding-tube compatibility

Many patients with severe metabolic disease may require enteral support. A delivery system designed for triheptanoin could target:

• Reduced tube occlusion
• Lower residual oil retention
• Easier flushing
• Compatibility with commonly used tube materials
• Controlled delivery without excessive foaming
• Reduced leakage at connectors

A tube-compatible administration kit could be sold to hospitals, metabolic clinics, specialty pharmacies, and home-care providers. The principal evidence package would involve physical compatibility, dose recovery, flow behavior, extractables and leachables, and cleaning or flushing procedures.

Oxidative stability and packaging

Triheptanoin is an unsaturated-free triglyceride, which may reduce oxidation risk relative to polyunsaturated oils, but lipid stability remains a packaging consideration. Commercial development can focus on:

• Low-oxygen headspace
• High-barrier bottle materials
• Light protection
• Closure systems that limit repeated air exchange
• Improved bulk-to-finished-product transfer controls
• Container systems that minimize product residue

Packaging claims are more defensible when supported by comparative stability data under ICH conditions. A new bottle or closure system could provide a practical lifecycle-management tool without changing the active formulation.

What formulations are protected by DOJOLVI-related intellectual property?

The principal intellectual-property value is likely concentrated in triheptanoin use for long-chain fatty acid oxidation disorders, manufacturing processes, formulation handling, and administration. The approved product’s simple composition limits the number of conventional formulation claims available to an innovator.

Potential claim categories include:

Claim category	Relevance to DOJOLVI
Triheptanoin composition	Protects pharmaceutical-grade active material or defined impurity profiles
Therapeutic use	Covers treatment of specific long-chain fatty acid oxidation disorders
Dosing regimen	May address weight-based dosing, caloric replacement, or titration
Manufacturing process	Covers purification, reaction conditions, control of fatty acid composition, or scale-up
Oral liquid product	May address concentration, purity, stability, or container closure
Administration device	May cover syringe, bottle adapter, or enteral delivery components
Combination product	May cover triheptanoin packaged with a specific dosing or feeding system

The FDA approval date establishes orphan-drug exclusivity but does not, by itself, establish patent coverage. DOJOLVI’s U.S. orphan exclusivity runs for seven years from the June 30, 2020 approval date, subject to the statutory orphan-drug framework. The expected U.S. orphan exclusivity date is June 30, 2027 [1, 2].

Patent term, Orange Book listing, and enforceability must be assessed separately from orphan exclusivity. An excipient or device strategy could remain commercially relevant after orphan exclusivity if it is supported by valid patent claims, regulatory exclusivity, switching costs, or supply-chain control.

When does DOJOLVI lose exclusivity?

DOJOLVI’s key U.S. regulatory exclusivity date is June 30, 2027, based on the FDA approval date and the seven-year orphan-drug exclusivity period [1, 2].

Protection or milestone	Date or status
FDA approval	June 30, 2020
U.S. orphan exclusivity	Expected through June 30, 2027
Dosage form	Oral liquid
Active ingredient	Triheptanoin
U.S. generic pathway	Potential ANDA or 505(b)(2), depending on product and regulatory strategy
Biosimilar pathway	Not applicable because triheptanoin is a synthetic small-molecule triglyceride, not a biologic
Pediatric exposure	Significant, with weight-based dosing and feeding-tube use
European orphan framework	Separate from U.S. exclusivity and jurisdiction-specific

Orphan exclusivity does not prevent all competing products. It generally blocks approval of the same drug for the same disease or condition unless statutory exceptions apply. A product with a different formulation, different indication, or legally distinct regulatory basis may present a separate analysis.

What generic entry risks exist for DOJOLVI?

The principal post-exclusivity risk is a generic or alternative triheptanoin oral liquid. A conventional ANDA would need to address pharmaceutical equivalence, bioequivalence, quality, and labeling requirements. An alternative concentration, different administration system, or clinically differentiated formulation could require a 505(b)(2) application rather than a straightforward ANDA.

Potential entry scenarios include:

1. A therapeutically equivalent triheptanoin oral liquid after the relevant exclusivity and patent barriers expire.
2. A 505(b)(2) product with a different concentration, flavor, packaging system, or dosing device.
3. A specialty-compounded product, although compounding does not provide the same regulatory status, quality system, or commercial scale as an approved generic.
4. A hospital or metabolic-clinic supply product designed for enteral administration.
5. A non-U.S. product entering markets with different orphan or patent constraints.

The strongest commercial defenses are likely to be patient-support infrastructure, clinical familiarity, supply reliability, physician education, and a delivery system that reduces caregiver burden. A simple oil formulation is easier to reproduce than a complex modified-release product, so manufacturing know-how and patient-service execution may matter more than excipient complexity.

Which companies could challenge DOJOLVI?

The most credible challengers are specialty-generic manufacturers, lipid-product manufacturers, and companies with experience in rare-disease oral liquids. Potential competitive capabilities include:

• GMP production of pharmaceutical triglycerides
• Large-volume lipid filling
• Pediatric liquid manufacturing
• Enteral administration devices
• Specialty-pharmacy distribution
• Rare-disease clinical and regulatory operations

No biosimilar competition is expected because DOJOLVI is not a biologic. The relevant competitors are generic small-molecule manufacturers and companies developing alternative triheptanoin products.

A challenger would need to overcome more than formulation replication. It would need to establish reliable active-ingredient sourcing, control fatty acid impurities, meet lipid stability specifications, validate packaging, and support complex dosing in children and adults.

What commercial opportunities exist for excipient suppliers?

The most attractive opportunities are adjacent to the approved product:

1. Excipient-free product support

Suppliers can offer low-extractables packaging, oxygen-control systems, lipid-compatible closures, and stability-indicating analytical services. These opportunities do not require changing the drug formulation.

2. Flavor and adherence systems

A supplier could develop a disease-compatible flavor platform that does not introduce clinically meaningful long-chain fats or carbohydrates. The strongest product would be validated for palatability across pediatric age groups and compatible with the labeled administration method.

3. Enteral delivery systems

A proprietary bottle adapter, syringe, connector, or dose-recovery system could generate device revenue and create switching costs. The product could be positioned for both DOJOLVI and other lipid-based oral medicines.

4. Pediatric packaging

Unit-dose or multi-dose packaging could reduce caregiver error and improve portability. Packaging should address the product’s oil phase, repeated opening, dose measurement, and home storage conditions.

5. Manufacturing services

Contract manufacturers with lipid-handling capabilities can compete for formulation scale-up, filling, packaging, stability testing, and process validation. Specialized manufacturing know-how may become more valuable as the market expands beyond a single branded product.

How strong is the commercial patent estate for an excipient strategy?

An excipient-only strategy is likely weaker than a combined product-and-device strategy. A generic flavor or standard bottle closure may be difficult to protect. Stronger claim positions could involve:

• A defined triheptanoin administration composition with a disease-compatible flavor system
• A package that improves dose recovery or stability
• A validated enteral delivery assembly
• A formulation with a specific impurity profile and shelf-life advantage
• A dosing system integrated with weight-based titration
• A combination of product, food matrix, and administration instructions

The commercial value of these claims depends on whether the competing product must practice them to achieve acceptable usability. Patents that cover optional presentation improvements may have limited blocking power. Claims tied to dose accuracy, tube delivery, or stability could create stronger practical barriers.

What is the FDA regulatory status of DOJOLVI?

DOJOLVI is an FDA-approved prescription drug for long-chain fatty acid oxidation disorders. It is an orphan-designated product and is regulated as a small-molecule drug, not a biologic [1, 2].

A reformulated product could require:

• A supplemental NDA if developed by the current sponsor
• A 505(b)(2) NDA for a materially different formulation or delivery system
• An ANDA for a therapeutically equivalent product
• Combination-product review if the delivery device is integral to administration
• New stability, extractables and leachables, compatibility, and human-factors data

A change that adds excipients, changes concentration, modifies taste, or introduces a new device could affect bioavailability, dose delivery, tolerability, labeling, and orphan-exclusivity analysis.

Key Takeaways

• DOJOLVI is a triheptanoin oral liquid with limited conventional excipient complexity.
• The best formulation opportunities are in administration, packaging, tube compatibility, stability, and palatability.
• Excipient selection must account for caloric contribution and the metabolic restrictions of the target population.
• DOJOLVI’s U.S. orphan exclusivity is expected to run through June 30, 2027.
• Biosimilar risk is not relevant; generic and 505(b)(2) competition are the relevant entry pathways.
• Device and packaging patents may offer stronger lifecycle-management opportunities than conventional excipient patents.
• Commercial differentiation will depend on dose accuracy, caregiver usability, supply reliability, and specialty distribution.
• Manufacturing controls for pharmaceutical-grade triheptanoin and lipid-compatible packaging may create meaningful barriers to entry.

FAQs

Can DOJOLVI be reformulated with conventional flavoring excipients?

Yes, but any reformulation would require assessment of caloric content, fatty acid composition, tolerability, stability, and regulatory impact. A co-packaged flavor or administration aid may present less regulatory risk than changing the drug product.

Is triheptanoin a lipid excipient or an active ingredient?

In DOJOLVI, triheptanoin is the active ingredient. It is a synthetic triglyceride that supplies medium-chain odd-carbon fatty acids for metabolic energy and anaplerosis.

Could a generic DOJOLVI use different excipients?

A generic or 505(b)(2) product could use a different formulation only if it satisfies the applicable FDA requirements for equivalence, safety, stability, labeling, and administration. Different excipients could affect regulatory classification and clinical bridging requirements.

Are enteral feeding tubes a significant commercial opportunity for DOJOLVI competitors?

Yes. A system that improves dose recovery, reduces leakage, and simplifies tube administration could support device claims, specialty distribution, and product differentiation, particularly in pediatric and medically complex patients.

Does DOJOLVI have biosimilar competition?

No. DOJOLVI is a synthetic small-molecule triglyceride product, not a biologic subject to the biosimilar pathway. Competition would arise through generic, 505(b)(2), specialty-compounded, or alternative triheptanoin products.

References

1. U.S. Food and Drug Administration. (2024). DOJOLVI (triheptanoin) oral liquid: Prescribing information. FDA.

2. U.S. Food and Drug Administration. (2024). Orphan drug designation and exclusivity. FDA.